REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)

DELAYED

^$ usd


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

1D

5D

1M

3M

YTD

1Y

3Y

1 Day REGN SPY QQQ SPX

Date

Time

Symbol

Headline

Impact

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $170.00 to $150.00. They now have a "hold" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Bank of America Co. from $575.00 to $547.00. They now have an "underperform" rating on the stock.

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications [Yahoo! Finance]

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications

Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S. [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $1,019.00 to $917.00. They now have a "buy" rating on the stock.

Date

Time

Symbol

Company Name

Action

%Chg

regeneron pharmaceuticals, inc.

regeneron pharmaceuticals, inc.

regeneron pharmaceuticals, inc.

regeneron pharmaceuticals, inc.

Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.

Date

Time

Action

From

To

Firm

Impact

%Chg

details

Canaccord Genuity

Leerink Partners

Date

Time

Symbol

Headline

Impact

Form PRE 14A REGENERON PHARMACEUTICAL For: Jun 13

Form SCHEDULE 13G/A REGENERON PHARMACEUTICAL Filed by: FMR LLC

Form 13F-HR REGENERON PHARMACEUTICAL For: Dec 31

Form 10-K REGENERON PHARMACEUTICAL For: Dec 31

Form 8-K REGENERON PHARMACEUTICAL For: Feb 04

Stock Stats

News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings

Order Stats
Sub-Penny

Odd Lot

Avg. bid-ask spread

Avg. bid / ask size

Shares at ask / bid

Off exchange

Top News Gainers

3/17 Regeneron Announces Important Advances in Novel COVID-19 Antibody Program 7.4%

11/5 Regeneron Reports Third Quarter 2019 Financial and Operating Results 6.9%

3/3 Regeneron Announces Upcoming Investor Conference Presentations 6.9%

5/8 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its "hold" rating re-affirmed by analysts at Canaccord Genuity. They now have a $353.00 price target on the stock, down previously from $408.00. 6.5%

4/15 Form 4 REGENERON PHARMACEUTICAL For: Apr 13 Filed by: STAHL NEIL 5.5%

4/16 Form 4 REGENERON PHARMACEUTICAL For: Apr 14 Filed by: LAROSA JOSEPH J 5.3%

2/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its price target raised by analysts at Citigroup Inc from $420.00 to $540.00. They now have a "buy" rating on the stock. 5.0%

11/8 U.S. company directors compensated more than ever, but now risk backlash [Reuters] 4.9%

10/10 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 4.7%

2/28 Form 4 REGENERON PHARMACEUTICAL For: Feb 26 Filed by: SING GEORGE L 4.5%

Top News Decliners

3/19 Coronavirus Proves Drug Companies To Be Innovators [Forbes] -10.3%

2/27 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -8.6%

3/11 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: YANCOPOULOS GEORGE -7.1%

5/7 Q1/2019 3/31/2019 EPS 4.450 ZacksConsensus 5.240 ActVsEst (0.790) - Miss -6.6%

4/20 Form 4 REGENERON PHARMACEUTICAL For: Apr 16 Filed by: LAROSA JOSEPH J -5.1%

8/14 Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol -4.1%

5/9 Form CT ORDER REGENERON PHARMACEUTICAL -3.5%

4/27 Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival -3.5%

4/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. They now have a $575.00 price target on the stock, up previously from $540.00. -3.3%

3/10 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: GOLDSTEIN JOSEPH L -3.3%

Don’t Miss Out On The Next BIG Stock Move

Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: